BR112016008901B1 - Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor - Google Patents

Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor Download PDF

Info

Publication number
BR112016008901B1
BR112016008901B1 BR112016008901-4A BR112016008901A BR112016008901B1 BR 112016008901 B1 BR112016008901 B1 BR 112016008901B1 BR 112016008901 A BR112016008901 A BR 112016008901A BR 112016008901 B1 BR112016008901 B1 BR 112016008901B1
Authority
BR
Brazil
Prior art keywords
adenosine
pain
methyl
group
compound
Prior art date
Application number
BR112016008901-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016008901A2 (pt
Inventor
Fang Jim-Min
Lin Yun-Lian
Lin Jung-Hsin
Lin Chun-Jung
Chern Yijuang
Huang Naikuei
Wang Hung-Li
Tu Benjamin Pang-Hsien
Chen Chih-Cheng
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of BR112016008901A2 publication Critical patent/BR112016008901A2/pt
Publication of BR112016008901B1 publication Critical patent/BR112016008901B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BR112016008901-4A 2013-10-23 2014-10-22 Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor BR112016008901B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894699P 2013-10-23 2013-10-23
US61/894,699 2013-10-23
PCT/US2014/061734 WO2015061426A1 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Publications (2)

Publication Number Publication Date
BR112016008901A2 BR112016008901A2 (pt) 2020-05-12
BR112016008901B1 true BR112016008901B1 (pt) 2022-08-23

Family

ID=52993493

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008901-4A BR112016008901B1 (pt) 2013-10-23 2014-10-22 Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor

Country Status (14)

Country Link
US (1) US10301348B2 (https=)
EP (1) EP3060566B1 (https=)
JP (1) JP6534997B2 (https=)
KR (1) KR102313314B1 (https=)
CN (1) CN106414456B (https=)
AU (1) AU2014340114B2 (https=)
BR (1) BR112016008901B1 (https=)
CA (1) CA2927699C (https=)
IL (1) IL245103B (https=)
MX (1) MX367707B (https=)
RU (1) RU2695358C2 (https=)
SG (1) SG11201603063WA (https=)
WO (1) WO2015061426A1 (https=)
ZA (1) ZA201603118B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675293B2 (en) * 2015-05-29 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
US11753432B2 (en) 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain
EP4476235A4 (en) * 2022-02-10 2026-02-18 Academia Sinica METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION
TWI910441B (zh) * 2022-07-07 2026-01-01 中央研究院 治療思覺失調症之方法及用於其中之組成物
CA3275345A1 (en) * 2022-12-29 2024-07-04 Academia Sinica METHODS FOR TREATING SLEEP DISORDERS AND COMPOSITION INTENDED FOR USE THEREOF
TW202500138A (zh) * 2023-03-17 2025-01-01 中央研究院 治療結節性硬化症或癲癇之方法及用於其中之組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8274187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
SG80526A1 (en) * 1990-09-25 2001-05-22 Rhone Poulenc Rorer Int Compounds having antihypertensive and anti- ischemic properies
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US20120295863A1 (en) * 2009-11-13 2012-11-22 Yun-Lian Lin Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
CA2783859A1 (en) * 2009-12-10 2011-06-16 Institute Of Materia Medica, Chinese Academy Of Medical Sciences N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof
WO2013120076A1 (en) 2012-02-09 2013-08-15 Brand Bumps, LLC Decorative detectable warning panel having improved grip
US20150038445A1 (en) * 2012-02-11 2015-02-05 Academia Sinica Methods and compositions for treating pain

Also Published As

Publication number Publication date
WO2015061426A1 (en) 2015-04-30
US20160264613A1 (en) 2016-09-15
NZ719740A (en) 2021-02-26
JP6534997B2 (ja) 2019-06-26
CA2927699C (en) 2022-07-05
EP3060566A4 (en) 2017-06-14
RU2016118282A (ru) 2017-11-28
CA2927699A1 (en) 2015-04-30
CN106414456B (zh) 2018-12-14
ZA201603118B (en) 2019-04-24
MX367707B (es) 2019-09-03
IL245103B (en) 2019-02-28
RU2016118282A3 (https=) 2018-06-18
AU2014340114A1 (en) 2016-05-26
IL245103A0 (en) 2016-06-30
KR20160086852A (ko) 2016-07-20
MX2016005174A (es) 2016-08-11
EP3060566A1 (en) 2016-08-31
AU2014340114B2 (en) 2018-10-18
JP2016535019A (ja) 2016-11-10
CN106414456A (zh) 2017-02-15
US10301348B2 (en) 2019-05-28
BR112016008901A2 (pt) 2020-05-12
RU2695358C2 (ru) 2019-07-23
KR102313314B1 (ko) 2021-10-19
SG11201603063WA (en) 2016-05-30
EP3060566B1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
BR112016008901B1 (pt) Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor
JP6923683B2 (ja) オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
ES2757948T3 (es) Compuestos heterocíclicos como inhibidores LSD1
US9938301B2 (en) Dihydropyrimido fused ring derivative as HBV inhibitor
Zhang et al. MANF protects dopamine neurons and locomotion defects from a human α-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways
JP6991993B2 (ja) 痛覚過敏を治療する方法
EP3781564A1 (en) Compounds for the treatment of cancer
NO322096B1 (no) Propargylfenyleter A2A-reseptoragonister, anvendelse derav samt farmasoytiske preparater omfattende forbindelsene.
TWI398255B (zh) 結合至腺苷酸ａａ受體和腺苷酸轉運子以預防及治療神經退化疾病的雙功能化合物
Chen et al. Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington's disease
JP7492005B2 (ja) ベンゼン環含有化合物及びその応用
CN114096552A (zh) 具有a2a腺苷受体拮抗作用的小分子化合物
TWI650328B (zh) 用於預防及治療神經退化疾病及疼痛之化合物
TWI668007B (zh) 用於預防及治療神經退化疾病及疼痛之化合物
KR20180101416A (ko) Cftr 조절제 및 이의 이용 방법
IL325115A (en) Lipids for use in lipid nanoparticles
IL325117A (en) Mixed amide ester-containing lipids for use in lipid nanoparticles
CN112218878A (zh) Ntcp抑制剂
WO2020192637A1 (zh) 固体形式的brd4抑制剂化合物及其制备方法与应用
CN108218946A (zh) 一种去氧胆酸类化合物、其制备方法及应用
BR122024024605A2 (pt) Compostos retinoides sintéticos, uso dos mesmos para o tratamento de uma doença ou condição que é aliviada pela ativação de rar e composição farmacêutica
HK1196035B (en) Opioid receptor ligands and methods of using and making same
NZ719740B2 (en) Compounds for use in prevention and treatment of neurodegenerative diseases and pain
BR112013024136B1 (pt) Compostos ligantes de receptor opióide, seu processo de preparação, composições farmacêuticas compreendendo os mesmos e seus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2574 DE 05/05/2020 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/10/2014, OBSERVADAS AS CONDICOES LEGAIS